What are the implications of FDA approval of PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? What are the implications for NGS-based molecular diagnostics?

What are the implications of FDA approval of PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? What are the implications for NGS-based molecular diagnostics?

What are the implications of the FDA having approved PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? And what are the implications for NGS-based molecular diagnostics?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

Medical Director & Consultant Medical Oncologist
The Cancer Centre (Singapore Medical Group)
Paragon Medical & Mt Elizabeth Novena
Specialist Centre Visiting Consultant
Mt Elizabeth Hospital & Mt Elizabeth Novena Hospital